BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BridgeBio Oncology Therapeutics (NASDAQ: BBOT) announced inducement stock-option grants awarded Feb 10, 2026, to two employees hired in January 2026 under its 2025 Inducement Plan.
The awards total 65,350 non-qualified stock options at an exercise price of $10.84 per share, vesting 25% after one year then monthly over 36 months. Grants were approved by the compensation committee under Nasdaq Listing Rule 5635(c)(4).
Details
News Market Reaction – BBOT
On Feb 12, the first trading day after this news, BBOT closed 5.15% below the previous close.
Data tracked by StockTitan Argus for the Feb 12 session.
Key Figures
- Current share price
- $10.84
- Closing price used as exercise price for inducement options
- Inducement option shares
- 65,350 shares
- Aggregate non-qualified stock options granted to new employees
- Par value
- $0.0001 per share
- Par value of BBOT common stock underlying inducement options
- Initial vesting tranche
- 1/4 of award
- Vests on first anniversary of employee start date
- Monthly vesting period
- 36 months
- Equal monthly installments after first anniversary, subject to service
- New hires covered
- 2 employees
- Inducement awards for individuals hired in January 2026
Historical Context
-
Stock option inducement grant for a new hire under 2025 Inducement Plan.
-
Preliminary Phase 1 safety and antitumor data across three RAS/PI3Kα programs.
-
Announcement of leadership presentation at the J.P. Morgan Healthcare Conference.
-
Inducement stock option grant for a November 2025 hire under Nasdaq Rule 5635(c)(4).
-
Late-breaking preclinical data on BBO-10203 as a first-in-class RAS:PI3Kα breaker.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
non-qualified stock options financial
inducement grants financial
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded inducement grants on February 10, 2026 under BBOT’s 2025 Inducement Plan as a material inducement to the employment of two individuals hired by BBOT in January 2026.
The employees received, in the aggregate, non-qualified stock options to purchase 65,350 shares of BBOT common stock, par value
All of the above-described Awards were granted outside of BBOT’s stockholder-approved equity incentive plans and are pursuant to BBOT’s 2025 Inducement Plan, which was adopted by BBOT’s board of directors in October 2025. The Awards were approved by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with BBOT in accordance with Nasdaq Listing Rule 5635(c)(4).
About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.
BBOT Contacts:
Investor Contact:
Heather Armstrong, Head of Investor Relations
BBOT
Investors@BBOTx.com
Media Contact:
Jake Robison
Inizio Evoke Comms
Jake.robison@inizioevoke.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.